J.P. Morgan Healthcare Conference Presentation
World leader in infectious diseases, £105bn market
Transforming prevention and treatment of infectious diseases for billions of people
2023 progress and what's next
Arexvy (RSV2, older adult)
>£3bn PYS³
⚫ First to receive approval
•
(US, EU, JP, UK)
Regulatory decision on at risk 50-59
adults expected in 2024
Shingrix (shingles)
>£4bn PYS³
⚫ Partnership with Zhifei in China.
.
Life-cycle innovation work ongoing
Influenza
>£3bn PYS³
Multivalent mRNA vaccine candidate
trials underway; phase II data H1 2024
Meningococcal disease
£1-2bn PYS³
•
MenABCWY US file submission
expected in H1 2024
.
Pneumococcal disease
>₤4bn PYS³
24v phase III start for adults and
resumption of paediatric phase II trial
in 2024
Bepirovirsen (Hepatitis B)
>£2bn PYS³
• Exclusive license for JNJ-3989 to
expand development
B-WELL phase III data from 2025
Anti-infectives
~£2bn PYS3
.
Preparing file submissions
for gepotidacin
⚫ Phase III trial underway for tebipenem
Herpes simplex virus
Phase I/II data in 2024
GSK
1. Evaluate Pharma, May 2023 2. Respiratory syncytial virus 3. PYS: Non-risk adjusted peak year sales potential is subject to certain assumptions consistent with those for previous outlooks, ambitions and expectations
6View entire presentation